Subscriber Only
Business
Deals
Tiny U.K. Biotech Takes On Glaxo’s $730,000 Gene Therapy
- Orchard’s version may reach more ‘bubble-boy disease’ patients
- Startup might be of interest as partner, Orchard CEO says

David Vetter, also known as Bubble Boy, interacts with medical professionals from inside a specially constructed sterile plastic bubble.
Baylor College of Medicine Photo ArchivesUpdated on